Starling Oncology (STLNW) Current Leases (2022 - 2026)

Starling Oncology (STLNW) has reported Current Leases for 5 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 3.91% year-over-year to $7.2 million; the trailing twelve-month figure through Jun 2026 stood at $7.2 million (up 3.91% YoY), and the FY2025 full-year result was $7.2 million, up 5.27% from the prior year.
• Current Leases eased to $7.2 million in Q2 2026 per STLNW's latest filing, from $7.4 million in the prior quarter.
• Across five years, Current Leases topped out at $7.4 million in Q1 2026 and bottomed at $4.3 million in Q1 2022.
• Historically, Current Leases has averaged $6.3 million across 5 years, with a median of $6.5 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Current Leases soared 33.77% in 2023, then gained 3.91% in 2026.
• Over 5 years, Current Leases stood at $5.5 million in 2022, then rose by 15.73% to $6.4 million in 2023, then grew by 6.84% to $6.8 million in 2024, then advanced by 5.27% to $7.2 million in 2025, then rose by 0.96% to $7.2 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $7.2 million, $7.4 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.